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The emergence of resistance to antimicrobial drugs in a range of bacterial pathogens of
the respiratory tract creates a challenge for the clinical diagnostic laboratory. Resistance
to macrolides among strains of Streptococcus pneumoniae has reached high levels in many
countries. There are two main types of resistance mechanisms, one (MLSB phenotype)
leading to high-level resistance and the other (Mphenotype) resulting in a lower level of
resistance. As there are indications that high-level resistance may have clinical relevance,
it is important to be able to detect such strains. This is now possible with the erythro-
mycin/clindamycin double disc diffusion test. Although resistance to b-lactams has also
increased, there is now evidence that some b-lactams are still effective against isolates
that have low-level resistance. In response to these observations, new breakpoints have
now been introduced by the National Committee for Clinical Laboratory Standards
(NCCLS) for amoxicillin, cefotaxime and ceftriaxone, which increase the percentage of
pneumococcal isolates that can still be treated effectively with these agents. As a
consequence of the increasing use of ﬂuoroquinolones, resistance has now emerged to
this group of compounds and this has been associated with clinical failures. Although
standard minimum inhibitory concentration tests can detect strains with high levels of
resistance (double step mutants) they are not reliable in detecting strains with a single
mutation. This is important as there is increasing evidence that strains with a single
mutation in the target topoisomerase are even more likely to develop a second mutation,
leading to higher levels of resistance and thus probably, therapeutic failure. Because
resistance to ﬂuoroquinolones is currently low in the US, the NCCLS does not recom-
mend that susceptibility testing with the newer respiratory ﬂuoroquinolones be carried
out routinely. However, since the respiratory ﬂuoroquinolones have in fact become the
ﬁrst line of therapy for the treatment of community-acquired pneumonia, it may now be
time to institute routine testing of clinical isolates of pneumococci to these agents. Simple
techniques for the clinical diagnostic laboratory to enable these ﬁrst-step mutants to be
detected are urgently required.
INTRODUCTION
During the last decade we have witnessed the
emergence of antimicrobial resistance in important
pathogens of the respiratory tract, including Strep-
tococcus pneumoniae, and Haemophilus inﬂuenzae.
The prevalence of multidrug resistance in pneu-
mococci has increased to over 20% in some coun-
tries and includes resistance to the b-lactams, the
macrolides and, more recently, the ﬂuoroquino-
lones. This has created a burden and a challenge to
the clinical diagnostic laboratory. This article will
discuss how the emergence of the different resist-
ance mechanisms and their increasing prevalence
may have an impact on the routine diagnostic
microbiology with respect to the changes in meth-
ods of testing the susceptibility of strains to macro-
lides, b-lactams and ﬂuoroquinolones and how
these results are reported to the clinician.
The emphasis of this paper is on pneumococci as
this species is the single most important pathogen
of the community. It is the commonest cause of
bacterial infections of the central nervous system,
of community-acquired pneumonia, of otitis
media in children and of sinusitis.
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MACROLIDE RESISTANCE IN
STREPTOCOCCUS PNEUMONIAE
The growth in resistance to macrolides among
pneumococci is unprecedented and in many coun-
tries has now reached over 30%. In the USA, for
example, a major surveillance study revealed that
the percentage of pneumococci resistant to macro-
lides almost doubled between 1995 and 1999
(10.6% in 1995 to 20.4% in 1999) [1]. Reports from
Italy show a dramatic increase in resistance to
macrolides among pneumococci in recent years,
with Oster et al. [2] reporting that resistance in
central Italy increased from 7.1% in 1993 to 32.8%
in 1997. The rate of resistance in pneumococci to
macrolides in Italy now exceeds that of resistance
to penicillins [3].
Resistance is particularly high in Asia, with over
65% resistance reported from China and Japan in
1998 [4]. One of the highest incidences of macro-
lide-resistant pneumococci was reported from Tai-
wan in 1997, where 82% of isolates were resistant
to erythromycin [5]. The latest results from the
Alexander Project indicate that by 2000 resistance
had reached 26% in the USA, whereas in the Far
East it was as high as 81% inHong Kong and 71.3%
in Japan (Figure 1).
A recent major survey in Canada showed a level
of 11.1% resistance among 2245 isolates [6]. Doern
et al. [7] reported recently that resistance among
pneumococcal isolates in the USA had increased
markedly between a survey performed in 1994–95
and a subsequent study carried out in 1999–2000.
There was a 16.1% increase in resistance to macro-
lides, the increase in multi-resistance was 13.3%
(see Table 1).
RESISTANCE MECHANISMS TO
MACROLIDES IN PNEUMOCOCCI
There are two major mechanisms of resistance to
macrolides in pneumococci and these account for
the vast majority of all resistant strains. In the ﬁrst,
the target site of binding of the macrolide is altered
by a methylase, these strains carry the ermB gene.
This gene encodes a 23S rRNA methylase which
methylates a speciﬁc adenine residue on the A2058
region of the ribosome and this results in confor-
mational change in the ribosome and reduced
binding of the antibacterial. The bacteria carrying
the ermB gene usually have the MLSB phenotype,
which means that they are resistant to the 14-, 15-
and 16-membered ring macrolides, as well as to
clindamycin and streptograminB. This type of
Figure 1 Macrolide resistance among
Streptococcus pneumoniae isolates from
various countries (resistance defined
as erythromycin MIC 1mg/L).
Alexander Project 2000, data on
file—GlaxoSmithKline (manuscript
in preparation).
Table 1 Increase in erythromycin and multi-resistance
among Streptococcus pneumoniae strains in the USA (per-
centage of isolates resistant)
Date
of survey
No. of
isolates
Resistant
to erythromycin
Multi-
resistant
1994–95 1527 10.3 9.1
1997–98 1601 19.2 16.0
1999–2000 1531 26.2 22.4
Data from three National Surveillance Studies; modified
from Doern et al. [7].
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modiﬁcation leads to a high level of resistance and
is typically constitutive in pneumococci. The MIC
values for erythromycin against these strains are
generally from 64mg/L to 256mg/L or above.
In the second type of resistance mechanism the
organism has an efﬂux pump [mediated by the
mefA gene] which exports the antibacterial agent
and thus protects the target site. The strains carry-
ing the mefA gene are resistant to the 14- and 15-
membered ring macrolides, and have the M
phenotype. This type of mechanism has been re-
cognized only recently and occurs in Streptococcus
pyogenes as well. The gene is now believed to be the
same in both species [8]. This type of resistance
gives low to intermediate levels of resistance to
macrolides. Typically the range of minimum in-
hibitory concentration (MIC) values for erythro-
mycin against such strains is from 0.5mg/L to
16mg/L.
Erythromycin and clindamycin susceptibility
phenotypes can be used in the routine clinical
laboratory to distinguish between target site mod-
iﬁcation (erm gene-mediated; MLSB phenotype)
and efﬂux resistance mechanisms (mef gene-
mediated; Mphenotype) in the majority of S. pneu-
moniae macrolide-resistant isolates [9–11]. Other
resistance mechanisms exist but are uncommon
[8,9,12–14]. Although susceptibility testing may
reliably distinguish the M from the MLSB pheno-
type in pneumococci, it cannot distinguish those
strains with ermB from those harboring both ermB
and mefA resistance determinants [8,15,16]. This
genotype, although increasing in prevalence in
some parts of the world, still remains less than
3% in most countries [9,12,16–18].
PREVALENCE OF THE DIFFERENT
TYPES OF RESISTANCE
The prevalence of these two major forms of resis-
tance differs in various parts of the world, with the
high-level MLSB type of resistance predominating
in Europe, Japan and South Africa. A study from
Italy found that the greatest proportion of resistant
strains carried the erm gene (76.5%) [8]. In France
themajority of strains (105 of 110) were found to be
carrying ermB genes [19]. Similarly in Belgium
very few macrolide-resistant pneumococci carried
the mefE gene (5/59 strains) [20] the remainder
were of the MLSB phenotype. In South Africa only
six of 36 erythromycin-resistant pneumococci car-
ried the mefE determinant [21]. In a Japanese
survey the two genes occurred alone in almost
equal proportions; 43.5% ermB and 40.3% mefE.
An additional 16.1% of strains carried both genes
[17].
In contrast, in the USA and Canada the efﬂux
mechanism is far more common, with approxi-
mately 60% of isolates carrying the mefA gene
[9]. The frequency of these strains among invasive
isolates was found to have increased in one survey
in the USA from 9% in 1994 to 26% of all isolates in
1999, whereas that of the MLSB type of resistance
remained fairly constant [22]. A major study by
Doern et al. [7] between 1999 and 2000 found that
66.5% of macrolide-resistant strains had a resist-
ance pattern consistent with the mefA genotype.
THE CLINICAL RELEVANCE OF
RESISTANCE TO MACROLIDES
The relevance of resistance to the clinical outcome
is not clear and moreover is controversial. There
are claims that patients infected with a macrolide-
resistant strain still respond to therapy but this is
not accepted by all. If resistance does not affect
outcome, why is this so? Lynch & Martinez [23]
have reviewed 23 reports in the literature of
instances of community-acquired pneumonia
caused bymacrolide-resistant pneumococci where
there have been therapeutic failures with macro-
lides. They emphasize that the picture is confused
by the complexities inherent in trying to assess the
reasons for therapeutic outcomes in community-
acquired pneumonia. They comment that ‘Clinical
failures often reﬂect factors independent of anti-
microbial susceptibility of the infecting organ-
isms’. The risk factors associated with a poor
response to therapy in patients with community-
acquired pneumonia are well documented and
include old age, co-morbidities and smoking [24]
Lynch & Martinez [23] did ﬁnd some well-
documented failures where the infecting pneumo-
coccal strain was shown to be resistant to the
macrolide used, but in contrast, the majority of
patients responded well to this class of drug. The
good tissue distribution and cell penetration of
macrolides, especially the newer agents, have often
been quoted as important factors. The authors
conclude that macrolides can still be considered
the drug of choice for the treatment of mild–
moderate community-acquired pneumonia in
previously healthy young adults, but recomm-
end broader treatment for patients requiring
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hospitalization. Patients with severe or life-threa-
tening community-acquired pneumonia, however,
should not receive macrolides alone. Their review
did not include any assessment of the type of
macrolide resistance in the strains isolated from
patients who did not respond to therapy so no
conclusions can be drawn regarding mechanisms
of resistance.
IDENTIFYING MACROLIDE
RESISTANCE
There have been some suggestions that high level
resistance may be associated with a higher rate of
failure so it may be important that the clinical
laboratory distinguishes between the two types
of resistance. The ranges of erythromycin MIC
values against strains give an indication of the
type of resistance, but there is an overlap between
ermB- and mefA-carrying strains (Figure 2).
The erythromycin/clindamycin double disc
(ECDD) diffusion test was ﬁrst described by Sep-
pala et al. [25], as a means of detecting high-level
resistance in Streptococcus pyogenes strains. A
recent study in Italy has shown that this technique
can also distinguish between the two types of
resistance in S. pneumoniae [8]. A total of 85 ery-
thromycin-resistant pneumococcal strains were
tested using the ECDD technique. The majority
of the strains (65) were classiﬁed as being resistant
to clindamycin as well as to erythromycin and
thuswere the constitutiveMLS phenotype (cMLS).
The remaining 20 strains were susceptible to
clindamycin and were thus assigned to the
Mphenotype. Polymerase chain reaction was used
to detect the presence of genes coding for resis-
tance to erythromycin (ermAM and mefE). The
cMLS strains were all found to carry the erm gene
and the Mstrains were all found to carry the mef
gene.
RESISTANCE TO b-LACTAM
ANTIBIOTICS IN S. PNEUMONIAE
There are several aspects of resistance to b-lactams
in pneumococci that have changed in recent years:
the emergence and spread of high-level resistance,
the clinical relevance of this resistance and a reas-
sessment of MIC susceptibility breakpoints. Strep-
tococcus pneumoniae used to be highly sensitive to
penicillins, with MIC values well below 0.1mg/L.
Strains then emerged with reduced susceptibility,
requiring 0.12–1mg/L for inhibition. This is
termed ‘intermediate resistance’. Some strains
were even less susceptible and are regarded as
fully resistant and they require 2mg/L or more for
inhibition. It is these strains that have shown a
dramatic increase in numbers in recent years. The
recent Alexander Project Survey (2000) revealed
that in the USA, Mexico and the Far East the
numbers of resistant strains of pneumococci
now outnumber those with intermediate resis-
tance. In Hong Kong there were 71.4% of strains
that were resistant, in Japan 30.9% and in the USA
22.1% (Figure 3).
In the USA during the 1980s the overall level of
penicillin resistance was only 3–5% and this was
only intermediate-type resistance. By the early
1990s the level had increased to 17.8% and now
included fully resistant strains. By 1994–95 23.6%
of pneumococcal strains were resistant and this
had increased by 1997–98 to 29.5%. In a compara-
tive study carried out in 1999–2000 not only had
the total percentage of non-susceptible strains
increased (to 34%), but for the ﬁrst time there were
more fully resistant strains and fewer strains with
intermediate resistance (see Table 2) [7].
THE CLINICAL RELEVANCE OF
PENICILLIN RESISTANCE
Despite the widespread prevalence of penicillin-
non-susceptible S. pneumoniae, the clinical impact
of using a b-lactam to treat a patient with a
respiratory tract infection caused by such a strain
is not clear [26–28]. Choi & Lee [29] analyzed 106
cases of invasive pneumococcal infection in
Korean children. Of the 72 non-meningeal pneu-
mococcal infections, 14 were caused by strains
Figure 2 Distribution of erythromycin resistance pheno-
types among 249 strains of erythromycin-resistant Strepto-
coccus pneumoniae collected by the Canadian Bacterial
Surveillance Network from across Canada in 2000.
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with intermediate resistance to penicillin and 18 by
strains that were highly resistant. Initial empiric
therapy regimens consisted of parenteral b-lac-
tams with or without an aminoglycoside. Over
half of the patients were immunocompromized.
They found that the outcomes of non-meningeal
infections caused by intermediate and highly
resistant pneumococci were not different from
those caused by penicillin-susceptible strains when
patients were treated with parenteral b-lactams.
Tan et al. [30] studied 254 children with pneumo-
coccal pneumonia. Twenty-two of the isolates had
intermediate resistance to penicillin and 14 were
highly resistant. Of the 14 patients infected with
the highly resistant strains, 12 received at least
one dose of an extended spectrum b-lactam. The
clinical presentation and outcome of therapy did
not differ signiﬁcantly between patients with
penicillin-susceptible vs. penicillin-non-suscept-
ible S. pneumoniae. However, the concept that
penicillin-non-susceptible S. pneumoniae are not
relevant with regards to the treatment of non-
meningeal infections with a penicillin has been
challenged in a paper published in 2000 by Feikin
et al. [24]. These authors examined the outcomes of
patients with invasive pneumococcal pneumonia
and they found that mortality was signiﬁcantly
associated with a penicillin MIC of 4mg/L or
higher (see Table 3). This was a population-based
epidemiological survey and thus the treatment
that individual patients received was not linked
with their infecting strain.
Another study carried out in Atlanta, USA,
attempted to assess the impact of penicillin resist-
ance on a group of patients with pneumococcal
bacteremia and pneumonia. These authors, recog-
nizing that mortality may be a rather crude mea-
sure of efﬁcacy, compared not just mortality but
also included medical complications and time to
clinical stability in patients infected with pneumo-
cocci fully susceptible to penicillins and with those
with reduced susceptibility [31]. A total of 23%
(44/192) patients were infected with strains with
reduced susceptibility and it was found that these
patients had an increased risk of death and of
suppurative complications. Even after adjusting
for differences in the severity of the illness at
baseline, there was a signiﬁcant association
Figure 3 Penicillin resistance among
isolates of Streptococcus pneumoniae
isolates from various countries. Alex-
ander Project 2000, data on file—
GlaxoSmithKline (manuscript in pre-
paration).
Table 2 Increase in penicillin- and
multi-resistance among Streptococcus
pneumoniae strains in the USA (per-
centage of isolates resistant)
Penicillin resistance
Date of
survey
No. of
isolates Total Intermediate High-level
Multi-
resistance
1994–95 1527 23.6 14.1 9.5 9.1
1997–98 1601 29.5 17.4 12.1 16.0
1999–2000 1531 34.2 12.7 21.5 22.4
Data from Three National Surveillance Studies; modified from Doern et al. [7].
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between infection with a strain of reduced sus-
ceptibility and of developing suppurative com-
plications (Table 4). The authors were not able to
include follow-up studies to determine, for exam-
ple, how soon a patient was able to return to
work.
Although both of these studies suffer from
drawbacks, they do give some indication that a
reduction in susceptibility in pneumococci to peni-
cillins may compromise therapy in some way.
They also illustrate how difﬁcult it is to determine
the effect of the drug in a complex medical situa-
tion. As the proportion and actual numbers of fully
resistant strains increase it is possible that their
impact on the outcome of therapy may become
clearer.
THE REASSESSMENT OF
BREAKPOINTS FOR b-LACTAMS
AGAINST PNEUMOCOCCI
Ever since the recognition of b-lactam resistance in
pneumococci, there has been controversy over the
relevance of the current breakpoints. The b-lactam
breakpoints were devised to detect a reduction in
susceptibility of meningeal pneumococcal isolates
so as to ensure optimal treatment. Since these
breakpoints were originally set, resistance has
increased and other drugs have become available
so it was thought appropriate to reassess the situa-
tion. Accordingly the National Committee of Clin-
ical Laboratory Standards (NCCLS) set new
breakpoints for amoxicillin and for cefotaxime
and ceftriaxone which came into force in January
2002 [32]. These are shown in Table 5. They differ
from the previous NCCLS breakpoints (M100-S11)
in that they introduce a new category for non-
meningeal isolates. For cefotaxime, the use of
interpretative criteria for non-meningeal infections
requires doses appropriate for serious pneumoco-
ccal infections (e.g. at least 1 g (adults) or 50mg/kg
(children) every 8 h or more frequently).
A study using The Surveillance Network data-
base looked at the possible impact that these new
Risk of death overall Risk of death after Day 4
Penicillin MIC (mg/L) Odds ratio 95% CIa Odds ratio 95% CI
4.0 2.3 0.7, 7.4 7.10 1.70, 30.0
2.0. 1.3 0.5, 3.7 0.65 0.08, 5.5
0.12–1.00 1.4 0.8, 2.6 1.00 0.30, 3.0
<0.12 reference – reference –
a95% CI¼ 95% confidence interval.
Adapted from Feikin et al. [24].
Table 3 Relationship between death
in patients with pneumococcal
pneumonia and the susceptibility
to penicillin of the infecting strain
Outcome
Penicillin Sa
(n¼ 148)
Penicillin Ra
(n¼ 44)
Relative riskb
(95% CI)
Death 16 (11%) 10 (23%) 1.7 (0.8, 3.4)
Respiratory failure 17 (11%) 8 (18%) 1.5 (0.7, 3.1)
Shock 12 (8%) 4 (9%) 1.0 (0.3, 2.9)
Admission to ICU 33 (22%) 11 (25%) 1.0 (0.6, 1.8)
Suppurative
complications
3 (2%) 4 (9%) 4.8 (1.2, 18.8)
aNumber of patients infected with penicillin-susceptible (S) and penicillin-
resistant (R) pneumococci.
bAdjusted relative risk for penicillin R vs. penicillin S, adapted from Metlay et al.
[31].
Table 4 Relationship between med-
ical outcome in patients with pneu-
mococcal pneumonia and the
susceptibility to penicillin of the
infecting strain
Table 5 New NCCLS breakpoints for cefotaxime and
ceftriaxone M100-S12
Susceptibility to penicillin (mg/L)
Site of infection Susceptible Intermediate Resistant
Meningitis 0.5 1.0 2
Non-meningeal 1.0 2.0 4
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breakpoints would have on the reported levels of
resistance among non-meningeal isolates of
S. pneumoniae [33]. The Surveillance Network data-
base allows access to the susceptibility of large
numbers of isolates from a variety of infection
sites. MIC values of isolates collected in the USA
between January 1996 and December 2000 were
collated and the numbers of strains that would be
classiﬁed as ‘susceptible’, ‘intermediate’ and
‘resistant’ to ceftriaxone and cefotaxime using
the new and the old breakpoints were calculated.
As can be seen in Table 6 the use of the new
breakpoints decreased substantially the numbers
of isolates that would be classiﬁed as resistant and
intermediate. Only 1% of isolates are now classi-
ﬁed as fully resistant and 3.1% as intermediate.
RESISTANCE TO
FLUOROQUINOLONE
ANTIBACTERIALS IN
S. PNEUMONIAE
Fluoroquinolones with increased activity against
S. pneumoniae, such as levoﬂoxacin, moxiﬂoxacin
and gatiﬂoxacin, are now being recommended and
used for the treatment of patients with commu-
nity-acquired pneumonia who are at risk of infec-
tion with multidrug-resistant strains [34–39].
Although the prevalence of levoﬂoxacin-resistant
S. pneumoniae is increasing in many parts of the
world, such resistance remains below 2% in most
parts of the world [7,40–45]. It is becoming increas-
ingly recognized, however, that, as opposed to b-
lactam and macrolide antibiotics, resistance to the
ﬂuoroquinolones can emerge de novo during treat-
ment and in some cases can be associated with
clinical failures [46–52].
There are two major issues with regard to the
susceptibility testing of pneumococci to the ﬂuoro-
quinolones, the ﬁrst is when to test and the second
is whether or not testing should be aimed at
detecting those strains that have ﬁrst-step muta-
tions. In the USA ﬂuoroquinolone resistance in
S. pneumoniae remains below 1% [53]. Therefore,
the NCCLS does not recommend that levoﬂoxacin,
gatiﬂoxacin, or moxiﬂoxacin be included in the
routine primary-testing panel for susceptibility
testing of pneumococci [32]. Since ﬂuoroquino-
lones are being recommended in some situations
for the empiric therapy of community-acquired
pneumonia, it may now be appropriate to consider
recommending routine testing and reporting of
pneumococcal susceptibilities to these agents.
There is increasing evidence that an isolate of
pneumococci with a mutation in one of the genes
encoding the target topoisomerase enzymes is
more likely to develop a second-step mutation
[54–56], suggesting that patients infected with a
strain that has a ﬁrst-step mutation should not be
treated with a ﬂuoroquinolone despite an MIC
which categorizes the agent as susceptible [57].
Previous studies have found that current NCCLS
criteria that deﬁne the susceptibility category for
levoﬂoxacin and moxiﬂoxacin do not always iden-
tify those isolateswithmutations [58–60]. Bast et al.
[58] characterized 61 pneumococcal isolates with
amino acid substitutions at Ser-79 or Asp-83 in
ParC and/or Ser-81 or Glu-85 in GyrA QRDRs.
Thirty-ﬁve of 36 isolates with only ParC amino
acid substitutions were susceptible to levoﬂoxacin
(MIC 2mg/L). Three isolates had amino acid
substitutions in both ParC and GyrA, yet were
susceptible to moxiﬂoxacin (MIC 1mg/L) (see
Table 7). The percentage of such isolates will
increase as ﬂuoroquinolone resistance in pneumo-
cocci increases. In addition this occurrence of iso-
lates with ﬁrst- and second-step mutations that are
still classiﬁed as susceptible will increase as ﬂuoro-
quinolones with even greater pneumococcal activ-
ity are developed and approved for the treatment
of pneumococcal infections.
INCREASING RESISTANCE TO
FLUOROQUINOLONES
There have been numerous reports showing the
gradual rise in resistance to the earlier ﬂuoro-
quinolones and, as is often the case, this can be
related to an increase in their use. In Canada
Table 6 Impact of changes in breakpoints for cefotaxime
and ceftriaxone on the resistance profiles of non-meningeal
isolates of Streptococcus pneumoniae
NCCLS
document
Susceptible
(%)
Intermediate
(%)
Resistant
(%)
Ceftriaxone (n¼ 9863)
M100-S11 82.7 13.2 4.1
M100-S12 95.9 3.1 1.0
Cefotaxime (n¼ 10 777)
M100-S11 79.2 14.3 6.5
M100-S12 93.5 4.2 2.3
Adapted from Sahm et al. [33].
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ciproﬂoxacin was used widely in the treatment of
acute exacerbations of chronic bronchitis but the
susceptibility of S. pneumoniae to ciproﬂoxacin had
not been tested as ciproﬂoxacin was not speciﬁ-
cally indicated for the speciﬁc treatment of pneu-
mococcal infections. When isolates were tested,
however, the emergence of resistance to ciproﬂox-
acin was revealed.
As part of the Canadian Bacterial Surveillance
Network, over 7500 isolates of S. pneumoniae were
collected from a variety of hospitals and clinics
throughout Canada [42]. The susceptibility of
these isolates to a range of ﬂuoroquinolones was
tested and these results were correlated with the
prescriptions of ﬂuoroquinolones/100 people.
Figure 4 shows the association between the
increase in prescriptions and the growth in the
numbers of resistant isolates. Resistance increased
dramatically from 1994 onwards. Similarly, a
recent Canadian survey of resistance to levoﬂox-
acin in pneumococci has shown the rise in the
percentage of resistant isolates from approxi-
mately 0.2% in 1998 to over 1% in 2001 [61].
Although 1 or 2% may seem very low, it has to
be remembered that this was the situation with
penicillin resistance in pneumococci less than
20 years ago.
In Hong Kong amarked increase in resistance to
ﬂuoroquinolones was noted in a survey carried
out in 1998 [62]. Ciproﬂoxacin, levoﬂoxacin and
the more active trovaﬂoxacin were tested for their
activity against 181 pneumococcal strains. The
percentage of strains resistant to ciproﬂoxacin
(MIC >2mg/L) was 12.1%, to levoﬂoxacin (MIC
>2mg/L) was 5.5% and there were 2.2% of strains
resistant (MIC >1mg/L) to trovaﬂoxacin. The
same authors carried out a more recent survey
which gave even more disquieting results [43].
This survey included the newer compounds mox-
iﬂoxacin and gatiﬂoxacin as well as ciproﬂoxacin
and levoﬂoxacin. A total of 180 isolates were col-
lected over a 4-month period in 2000. Of these, 88
were fully resistant to penicillin, 21 were of inter-
mediate resistance and 71 were susceptible to
penicillin. The level of resistance to ciproﬂoxacin
had risen to 17.8% but resistance was also seen to
moxiﬂoxacin (8.9% of strains) and to gatiﬂoxacin
(12.2% of strains). There was a clear association
with penicillin resistance, with a higher percentage
of the penicillin-resistant strains having dimin-
ished susceptibility to all four of the ﬂuoroquino-
lones, whereas with ciproﬂoxacin as many as 33%
of penicillin-resistant isolates were also resistant to
ciproﬂoxacin. These results are shown in Table 8.
Table 7 Activity of fluoroquinolones against isolates of Streptococcus pneumoniae with or without QRDR parC or parC and
gyrA amino acid substitutions (all isolates were resistant to ciprofloxacin, MIC 4mg/L)
QRDR substitution Number of isolates with stated MIC (mg/L)
parC GyrA 0.25 0.5 1 2 4 8
Levofloxacin þ  – – 5 30 1 0
þ þ a –a –a –a 2 24
Gatifloxacin þ  3 29 4 – – –
þ þ –a –a –a 8 13 5
Moxifloxacin þ  32 3 1 – – –
þ þ –a –a 5a 13 6 2
adenotes susceptible category.
Adapted from Bast et al. [58].
Figure 4 Association between fluoroquinolone prescrip-
tions per capita and percentage of pneumococci with
reduced susceptibility to fluoroquinolones in Canada in
two age groups. Solid bars represent 15–64-year age group;
open bars represent >65-year age group. Reproduced from
Chen et al. [42] with permission.
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The resistant strains were all isolates from
adults and there was an overall rate of non-
susceptibility to levoﬂoxacin of 13.3%. The inci-
dence of resistance was highest in those patients
aged over 65 (17.1%) and those with chronic ob-
structive pulmonary disease (24.6%). There was
evidence that the resistance was caused by a clone
which was related genetically to the Spanish 23F
clone. As with Chen et al. [42], these authors noted
the increase in use of ﬂuoroquinolones between
1994 and 1999.
THE CLINICAL RELEVANCE OF
FLUOROQUINOLONE RESISTANCE
IN S. PNEUMONIAE
Clinical failures in pneumonia associated with
ﬂuoroquinolone resistance in pneumococci,
although anecdotal, have been well described
[47–50,52,63–66]. Reports of the development of
resistance and clinical failures appeared shortly
after the introduction of ciproﬂoxacin in 1987 [66–
70]. Weiss et al. [52] described a nosocomial out-
break of ﬂuoroquinolone-resistant pneumococci.
Over the course of a 20-month period in a hospital
respiratory ward, where ciproﬂoxacin was often
used as empiric antimicrobial therapy for lower res-
piratory tract infections, 16 patients with chronic
bronchitis developed lower respiratory tract infec-
tions caused by a strain of S. pneumoniae (serotype
23F) resistant to penicillin and ciproﬂoxacin. The
MIC of ciproﬂoxacin for all isolates was 4mg/L.
All ﬁve patients with acute exacerbation of chronic
bronchitis (AECB) treated with ciproﬂoxacinfailed
therapy. Davidson et al. [47] report four cases of
pneumococcal pneumonia, treated empirically
with oral levoﬂoxacin, that failed therapy. All
cases were associated with the isolation of an
organism that was either resistant to levoﬂoxacin
prior to therapy or which had acquired resistance
during therapy. Two patients had previously been
on ciproﬂoxacin. One of the four patients died after
6 days of monotherapy with levoﬂoxacin.
From these and other studies a number of risk
factors have been recognized that identify patients
who are likely to be colonized or infected with a
ﬂuoroquinolone-resistant pneumococcus: patients
who are>64 years of age, have a history of chronic
obstructive lung disease and/or prior exposure to
ﬂuoroquinolones [18,41–43]. None of the commu-
nity-acquired pneumonia position papers pub-
lished since the introduction of the ‘respiratory’
ﬂuoroquinolones have suggested that a history of
previous ﬂuoroquinolone use should be a reason
for caution when using one of these antimicrobials
empirically [34,36–38].
CONCLUSIONS
The spread of multi-resistance among Streptococ-
cus pneumoniae strains is unlikely to stop and may
compromize the value of established antibacterial
agents. The clinical signiﬁcance of resistance to
both macrolides and b-lactam agents is controver-
sial, but there are indications that clinical failures
or complicationsmay be related to resistance under
certain circumstances. As high-level resistance to
penicillins and to macrolides increases, this may
have more clinical relevance. Resistance to ﬂuor-
oquinolones is currently relatively low, but would
also appear to be increasing and has already led to
clinical failures. Since the use of these agents is
increasing, this may present a new problem.
The type of resistance mechanism may have an
impact on clinical response and it is therefore
important that the clinical microbiology laboratory
attempts to distinguish between the varyingmech-
anisms. Withmacrolides, the double disc diffusion
method is a valuable, simple tool to distinguish a
strain with an efﬂux mechanism from the MLSB
phenotype. With ﬂuoroquinolones, there are prob-
lems. Single-step mutants are frequently still
Table 8 MIC values (mg/L) of fluoroquinolones against
180 isolates of Streptococcus pneumoniae from Hong Kong in
2000 and the percentage of strains resistant
Fluoroquinolone
MIC90
(mg/L)
%
resistant
Ciprofloxacin All 32 17.8
Pen S 2.00 4.2
Pen I 2.00 0.0
Pen R 32 33.0
Levofloxacin All 32 13.3
Pen S 1.00 0.0
Pen I 1.00 0.0
Pen R 32 27.3
Gatifloxacin All 6.00 12.2
Pen S 0.38 0.0
Pen I 0.25 0.0
Pen R 8.00 25.0
Moxifloxacin All 2.00 8.9
Pen S 0.19 0.0
Pen I 0.19 0.0
Pen R 4.00 18.2
Adapted from Ho et al. [43].
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susceptible to thenewerﬂuoroquinolones,although
at the top of the range of susceptibility and thus
cannot be detected byMICmethods. Most double-
step mutants will have diminished susceptibility
and this may be evident from an MIC determina-
tion. It is, however, important that these ﬁrst-step
mutants are detected since there is evidence that
they may acquire a second mutation during ther-
apy. Simple techniques are urgently required to
detect such strains.
The recognition by the NCCLS that previous
susceptibility breakpoints for cefotaxime and cef-
triaxone were too conservative for interpreting the
results of susceptibility testing in vitro of pneu-
mococci that were isolated from patients with non-
meningeal infections is a step forward. The appro-
priate incorporation of these new guidelines will
reduce the number of pneumococcal isolates
reported as intermediate or resistant signiﬁcantly,
thereby providing physicians with more therapeu-
tic options in this era of ever increasing anti-
microbial resistance.
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